Floatz logo

mp-101

Aggression

Mediti Pharma Inc.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Aggression cohort.

Asset / SponsorPhaseRating
Olanzapine
Washington University School of Medicine
Phase 4BBB
Risperdal
Washington University School of Medicine
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Intramuscular Olanzepine
Christian Medical College, Vellore, India
Phase 3BB
Promethazine
Christian Medical College, Vellore, India
Phase 3BB

View all 10 →

Same molecule, other indications

mp-101 is also rated in:

psychotic disorderDormant
CCC
Indicative ·
53 / 100
View asset →
dementiaDormant
CCC
Indicative ·
53 / 100
View asset →
AgitationDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →